Targeted prostate cancer treatment cuts risk of side effects, study suggests
An NHS trial over 10 years followed nearly 3,500 men who received focal therapy, a less invasive treatment.
A recent study suggests that a targeted treatment for prostate cancer may significantly reduce the risk of side effects associated with traditional treatments. The 10-year NHS trial, which followed nearly 3,500 men, used focal therapy, a less invasive approach that targets only the affected areas of the prostate. This is a promising development for the estimated 1 in 8 men who will be diagnosed with prostate cancer in their lifetime.
The study's findings are significant because traditional treatments for prostate cancer, such as surgery or radiotherapy, can often result in side effects like incontinence and impotence. Focal therapy, on the other hand, aims to minimize damage to healthy tissue, potentially reducing the risk of these side effects. This treatment approach has been gaining attention in recent years, with several studies suggesting its effectiveness in treating localized prostate cancer.
As the study's results are further analyzed and verified, it's likely that focal therapy will become an increasingly popular treatment option for men with prostate cancer. What's next to watch is how this treatment approach will be integrated into mainstream care and whether it will be made widely available on the NHS. Additionally, further research is needed to determine the long-term effectiveness of focal therapy and its potential applications in treating other types of cancer.
Originally reported by bbc.co.uk. NewsDebate adds analysis for general news readers.